RxDoctor Payments Data

Anthony Garcia, MD

Cardiovascular Disease · Amityville, NYNPI 1437307816

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 38 payments — averaging $39.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$494
  • Amgen$179
  • Johnson & Johnson$146
  • Bayer$132
  • Boston Scientific$61
  • Merck$60
  • plus $415 from 12 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,486 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$207,655
Medicare patients
267
Services billed
10,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$96,702
JardianceEmpagliflozin52$51,237
Repatha SureclickEvolocumab30$37,520
EntrestoSacubitril/Valsartan31$28,795
XareltoRivaroxaban16$23,891
MounjaroTirzepatide23$22,055
BrilintaTicagrelor18$15,612
FarxigaDapagliflozin Propanediol11$7,483
VascepaIcosapent Ethyl17$6,049
Rosuvastatin Calcium134$2,565
Metoprolol Succinate127$2,472
Arnuity ElliptaFluticasone Furoate11$2,255
Atorvastatin Calcium181$1,732
Losartan Potassium110$1,355
Ezetimibe17$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$96,70271 claims
Boehringer IngelheimJardiance$494$51,23752 claims
NovartisEntresto$43$28,79531 claims
Johnson & JohnsonXarelto$146$23,89116 claims
AstraZenecaBrilinta, Farxiga$30$23,09529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →